Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REFIFI: Response-adaptive epcoritamab in first relapse/refractory large B-cell lymphoma
2024-514440-86-00Phase 2Authorised
- Sponsor
- GELTAMO
- Start
- Aug 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of epcoritamab in diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), large-cell lymphoma and 1 more (2 arms), sponsored by GELTAMO. Primary endpoint: Best complete response rate with epcoritamab monotherapy. Planned start Aug 2025; status: authorised.
02
Drugs
epcoritamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)large-cell lymphomafollicular lymphoma (FL)
Beyond the preview
Go deeper on 2024-514440-86-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514440-86-00.